Literature DB >> 32704092

Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy.

Torben Rixecker1, Vadim Lesan2, Manfred Ahlgrimm2, Lorenz Thurner2, Moritz Bewarder2, Niels Murawski2, Konstantinos Christofyllakis2, Sarah Altmeyer2, Angelika Bick2, Stephan Stilgenbauer2, Joerg Thomas Bittenbring2, Dominic Kaddu-Mulindwa2.   

Abstract

Patients undergoing intensive chemotherapy are usually in need for central venous catheters (CVC). Due to contradictory study results, relation of insertion site and CVC-associated complication rate in these patients is not clear. We therefore retrospectively analyzed CVC-related data of all patients undergoing intensive chemotherapy with high risk of febrile neutropenia according to NCCN criteria, who received a CVC at our bone marrow transplantation unit between May 2016 and December 2019. In total, 210 patients received 281 CVC. CVC were placed via either the subclavian-vein (SCV, n = 58; 20%) or the internal-jugular-vein (IJV, n = 223; 80%). Median duration of CVC-lifetime and neutropenic days per CVC were comparable between the two groups (IJV vs SCV: 23 days vs 21 days (p = 0.16) and 12 days vs 11 days (p = 0.65)). Both, time to CVC removal due to local inflammation and time to central line-associated bloodstream infection was significantly shorter in patients with SCV catheters (p = 0.013 and p = 0.045). CVC placed in the IJV were associated with significantly less catheter-related infectious events compared with CVC placed in the SCV. This difference was consistent across different subgroups including 88 patients undergoing allogeneic stem cell transplantation.

Entities:  

Mesh:

Year:  2020        PMID: 32704092     DOI: 10.1038/s41409-020-01003-0

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  16 in total

1.  Central venous catheter-associated bloodstream infection and colonisation of insertion site and catheter tip. What are the rates and risk factors in haematology patients?

Authors:  Dirk Luft; Claudia Schmoor; Christine Wilson; Andreas F Widmer; Hartmut Bertz; Reno Frei; Dominik Heim; Markus Dettenkofer
Journal:  Ann Hematol       Date:  2010-06-08       Impact factor: 3.673

2.  Essential, but at what risk? A prospective study on central venous access in patients with haematological malignancies.

Authors:  C H K Dix; D T O Yeung; M L Rule; D D F Ma
Journal:  Intern Med J       Date:  2012-08       Impact factor: 2.048

3.  Intravascular Complications of Central Venous Catheterization by Insertion Site.

Authors:  Jean-Jacques Parienti; Nicolas Mongardon; Bruno Mégarbane; Jean-Paul Mira; Pierre Kalfon; Antoine Gros; Sophie Marqué; Marie Thuong; Véronique Pottier; Michel Ramakers; Benoît Savary; Amélie Seguin; Xavier Valette; Nicolas Terzi; Bertrand Sauneuf; Vincent Cattoir; Leonard A Mermel; Damien du Cheyron
Journal:  N Engl J Med       Date:  2015-09-24       Impact factor: 91.245

4.  National Healthcare Safety Network (NHSN) Report, data summary for 2006 through 2007, issued November 2008.

Authors:  Jonathan R Edwards; Kelly D Peterson; Mary L Andrus; Margaret A Dudeck; Daniel A Pollock; Teresa C Horan
Journal:  Am J Infect Control       Date:  2008-11       Impact factor: 2.918

5.  Surveillance for catheter-associated bloodstream infection in hematology units: quantifying the characteristics of a practical case definition.

Authors:  Leon J Worth; James Black; John F Seymour; Karin A Thursky; Monica A Slavin
Journal:  Infect Control Hosp Epidemiol       Date:  2008-04       Impact factor: 3.254

6.  Maea expressed by macrophages, but not erythroblasts, maintains postnatal murine bone marrow erythroblastic islands.

Authors:  Qiaozhi Wei; Philip E Boulais; Dachuan Zhang; Sandra Pinho; Masato Tanaka; Paul S Frenette
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

7.  Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures.

Authors:  F Blot; G Nitenberg; E Chachaty; B Raynard; N Germann; S Antoun; A Laplanche; C Brun-Buisson; C Tancrède
Journal:  Lancet       Date:  1999-09-25       Impact factor: 79.321

8.  Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology.

Authors:  M Hentrich; E Schalk; M Schmidt-Hieber; I Chaberny; S Mousset; D Buchheidt; M Ruhnke; O Penack; H Salwender; H-H Wolf; M Christopeit; S Neumann; G Maschmeyer; M Karthaus
Journal:  Ann Oncol       Date:  2014-01-07       Impact factor: 32.976

9.  Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices.

Authors:  Leon J Worth; John F Seymour; Monica A Slavin
Journal:  Support Care Cancer       Date:  2008-12-19       Impact factor: 3.603

10.  Surveillance with successful reduction of central line-associated bloodstream infections among neutropenic patients with hematologic or oncologic malignancies.

Authors:  Iris F Chaberny; Evelina Ruseva; Dorit Sohr; Stefanie Buchholz; Arnold Ganser; Frauke Mattner; Petra Gastmeier
Journal:  Ann Hematol       Date:  2009-01-13       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.